Last reviewed · How we verify
Amoxicillin/clavulunate potassium
Amoxicillin/clavulanate is a beta-lactam antibiotic combination that kills bacteria by inhibiting cell wall synthesis, with clavulanate protecting amoxicillin from degradation by bacterial beta-lactamases.
Amoxicillin/clavulanate is a beta-lactam antibiotic combination that kills bacteria by inhibiting cell wall synthesis, with clavulanate protecting amoxicillin from degradation by bacterial beta-lactamases. Used for Bacterial infections caused by susceptible organisms including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and otitis media.
At a glance
| Generic name | Amoxicillin/clavulunate potassium |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Beta-lactam antibiotic with beta-lactamase inhibitor |
| Target | Penicillin-binding proteins (PBPs); bacterial beta-lactamases |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Amoxicillin works by binding to penicillin-binding proteins and inhibiting bacterial cell wall cross-linking, leading to cell lysis and death. Clavulanic acid is a beta-lactamase inhibitor that prevents bacterial enzymes from breaking down amoxicillin, thereby extending its spectrum of activity against beta-lactamase-producing organisms.
Approved indications
- Bacterial infections caused by susceptible organisms including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and otitis media
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Rash
- Abdominal pain
- Allergic reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amoxicillin/clavulunate potassium CI brief — competitive landscape report
- Amoxicillin/clavulunate potassium updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI